APA (7th ed.) Citation

B, S., S, C., S, X., R, W., S, R., T, S., . . . CS, T. (2025). Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leukemia & lymphoma, 66(12), 2238. https://doi.org/10.1080/10428194.2025.2541911

Chicago Style (17th ed.) Citation

B, Shah, et al. "Zanubrutinib Versus Acalabrutinib Indirect Treatment Comparison in Relapsed or Refractory Mantle Cell Lymphoma." Leukemia & Lymphoma 66, no. 12 (2025): 2238. https://doi.org/10.1080/10428194.2025.2541911.

MLA (9th ed.) Citation

B, Shah, et al. "Zanubrutinib Versus Acalabrutinib Indirect Treatment Comparison in Relapsed or Refractory Mantle Cell Lymphoma." Leukemia & Lymphoma, vol. 66, no. 12, 2025, p. 2238, https://doi.org/10.1080/10428194.2025.2541911.